Opthea to present data from Phase 2b trial of sozinibercept at the Macula Society 48th Annual Meeting
David S. Boyer, MD will present data from the sozinibercept Phase 2b wet AMD trial.
(Image credit: AdobeStock/Anton Gvozdikov)
Opthea is set to highlight sozinibercept during an oral presentation at the Macula Society 48th Annual Meeting. This meeting is being held February 12-15, 2025, in Charlotte Harbor, Florida.1
The presentation details are as follows:
- Session: Neovascular AMD I: Trials
- Date: Friday, February 14, 2025
- Time: 8:00 to 8:05 AM ET
- Presentation title: Sozinibercept Combination Therapy for Neovascular Age-Related Macular Degeneration: Subgroup Analysis of a Phase 2b Study to Assess the Angiographic Predictors of Response
- Presenter: David S. Boyer, MD
In his presentation, David S. Boyer, MD will present data from the sozinibercept Phase 2b wet AMD trial which demonstrated that superior vision and anatomic outcomes were observed with sozinibercept 2 mg combination therapy when compared with standard-of-care ranibizumab alone, with baseline angiographic lesion characteristics predictive of response.1
This presentation follows Opthea’s Investor Day, which took place in New York City, New York on January 28, 2025. At this event, the company shared how it was preparing for the anticipated topline data readout of its two pivotal trials, COAST in early CY Q2 2025 and ShORe in mid-CY 2025. Charles C. Wykoff, MD, PhD spoke during this session to discuss the potential of this candidate to work in combination with standard-of-care anti-VEGF therapies and the potential benefit for better vision outcomes for patients with wet AMD.2
